Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) issued its earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), RTT News reports. The firm had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. During the same quarter in the previous year, the business posted ($0.18) EPS. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $15.48 on Friday. The company’s fifty day moving average price is $14.11 and its two-hundred day moving average price is $13.16. The firm has a market capitalization of $689.94 million, a P/E ratio of -28.67 and a beta of 0.68. Y-mAbs Therapeutics has a 12 month low of $4.69 and a 12 month high of $20.90.

Insider Activity

In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the transaction, the chief operating officer now owns 30,600 shares in the company, valued at approximately $449,514. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock worth $1,338,100 over the last ninety days. Corporate insiders own 22.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on YMAB. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. BMO Capital Markets decreased their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Morgan Stanley cut their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.